Phio Pharmaceuticals (NASDAQ:PHIO) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Phio Pharmaceuticals (NASDAQ:PHIO) in a report released on Thursday, MarketBeat Ratings reports. The brokerage issued a buy rating and a $14.00 price target on the stock. HC Wainwright also issued estimates for Phio Pharmaceuticals’ Q2 2025 earnings at ($0.36) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS, FY2026 earnings at ($0.83) EPS and FY2027 earnings at ($0.41) EPS.

Phio Pharmaceuticals Price Performance

Shares of PHIO stock opened at $2.96 on Thursday. The firm has a market cap of $14.20 million, a P/E ratio of -0.27 and a beta of 0.84. Phio Pharmaceuticals has a 1-year low of $0.97 and a 1-year high of $9.79. The firm has a fifty day moving average of $1.92 and a two-hundred day moving average of $2.01.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC acquired a new position in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned approximately 0.59% of Phio Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 57.31% of the company’s stock.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.